Phase II Evaluation of 5-Fluorouracil and Low-Dose Leucovorin in Cisplatin-Refractory Advanced Ovarian Carcinoma
Thirty-nine women with advanced, recurrent epithelial ovarian carcinoma who failed prior treatment with a platinum-based regimen were treated with leucovorin, 20 mg/m2 intravenously followed by 5-fluorouracil, 425 mg/m2 intravenously, daily for 5 consecutive days every 5 weeks in a phase II trial. P...
Saved in:
Published in | Gynecologic oncology Vol. 54; no. 2; pp. 180 - 183 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
San Diego, CA
Elsevier Inc
01.08.1994
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Thirty-nine women with advanced, recurrent epithelial ovarian carcinoma who failed prior treatment with a platinum-based regimen were treated with leucovorin, 20 mg/m2 intravenously followed by 5-fluorouracil, 425 mg/m2 intravenously, daily for 5 consecutive days every 5 weeks in a phase II trial. Partial regressions were seen in 3 of 15 (20%) measurable disease patients, and objective regressions were seen in 3 of 14 (21%) evaluable/nonmeasurable disease patients. A 50% or greater decrease in CA-125 level was observed in 3 of 10 (30%) patients with no objectively evaluable or measurable disease. Overall objective response rate was 23% (95% confidence interval: 11 to 39%) in all 39 patients evaluated, with a median time to progression of 3 months and overall median survival of 7 months. Toxicities were acceptable and consisted of neutropenia, thrombocytopenia, stomatitis, and mild diarrhea. 5-Fluorouracil, as administered in this protocol, had modest antitumor activity in cisplatin-refractory ovarian carcinoma of short duration and minimal toxicity. |
---|---|
ISSN: | 0090-8258 1095-6859 |
DOI: | 10.1006/gyno.1994.1190 |